Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past efforts by other drug developers have mostly been unsuccessful. More: Lenz's Vizz wins FDA approval to crack 'large, untapped' market
read moreAs Moderna plows ahead with its multiyear cost-savings scheme, the mRNA specialist delivered a better second quarter than expected, despite sales of its vaccines still leaving something to be desired. More: Despite ongoing decline, Moderna's Spikevax sales beat expectations in
read moreIn honor of the annual World Lung Cancer Day commemoration on Aug. 1, Johnson & Johnson has unveiled a new initiative encouraging patients to speak up in the treatment decision-making process. More: J&J coins the term ‘3rd opinion,’ debuts awareness
read moreA stellar launch of Amvuttra in the rare heart disease ATTR-CM has boosted Alnylam’s market cap above $50 billion. More: Alnylam exceeds B market cap as Amvuttra heart disease launch wows Wall Street Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals